problems with glp-1 drugs Researchers find medications safe to continue before surgery in patients diabetes and obesity How GLP-1 weight loss medications

Exec SummaryDanuglipron is an experimental weight loss medication being developed by Pfizer

Due to a short plasma half-life of native GLP-1, several synthesized GLP-1 receptor agonists (RAs) were developed for type 2 diabetes mellitus (DM) treatment

With the participation of researchers from the Paul Langerhans Institute Dresden (PLID), partner at the German Center for Diabetes Research, a GLP-1 receptor agonist in the form of tablets could for the first time be compared with the most common second-line therapy of T2D, a DPP-IV inhibitor

Both glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors can reduce CV risk in patients with T2D, and both are recommended by the American Diabetes Association to reduce the risk of major cardiovascular events (MACE)

Adults with obesity and autoimmune disease taking GLP-1 medication experience fewer cardiac events and have a lower risk of death, according to new findings.

Liraglutide offers an affordable GLP-1 option for managing antipsychotic weight gain.